Non-invasive Brain Tumor Molecular Diagnostics and Monitoring
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Diagnostic test.
- Who it may be relevant to
- Registry conditions: Brain Tumor. Basic parameters: 18 years — 99 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Czechia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Non-invasive Brain Tumor Diagnosis Through Analysis of Proximal Fluids, Circulating Tumor Cells, and Biomolecules
Overview
This prospective multicenter study aims to enroll GBM patients who will undergo repeated assessments (preoperatively and 3 months post-surgery) to detect circulating tumor cells and analyze the transcriptomic profiles of EVs in their blood. The prognostic and monitoring significance of these biomarkers to disease course (assessing treatment efficacy, resistance incidence, tumor progression) will be evaluated. Concurrently, proteomic profiles typical of GBM will be analyzed in blood and ocular secretion samples from GBM patients, patients with low-grade gliomas, and patients without brain tumors to identify and validate novel protein biomarkers suitable for disease monitoring. Additionally, this study proposes an innovative approach to monitor GBM patients by investigating the presence of GBM-specific nucleic acid fragments in urine.
Interventions
- Diagnostic test Diagnostic test
No intervention among the arms. The diagnostic, prognostic, predictive and follow-up value of tested biomolecules will be analyzed.
Primary outcome measures
- Proteomic profiles of proximal liquids in brain tumor patients [Time frame: 2020-2023]
- Circulating tumor cells (CTCs) for non-invasive monitoring of GBM patients. [Time frame: 2020-2030]
- Extracellular vesicles (EVs) for non-invasive monitoring of GBM patients. [Time frame: 2020-2030]
- Urine as a source of GBM-specific nucleic acids fragments for disease monitoring. [Time frame: 2025-2030]
Eligibility criteria
Inclusion Criteria: Adult patients with brain tumors -
Exclusion Criteria: No other cancer; no inflammatory disease
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Czechia · 1 center
- Department of Neurosurgery, University Hospital Olomouc — Olomouc
Identifiers
NCT: NCT06501521 · NW25-03-00198